Patent ID: 9221806
Filing Date: 2015-12-29
Classification: A61K,A61P,C07D

Abstract:
1. A method for the therapeutic treatment of a disease in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role and wherein the disease treated is: a solid tumour which is a tumour of the squamous epithelium, the bladder, the stomach, the kidneys, the head or neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the uro-genital tract, the lymphatic system, the stomach, the larynx or the lung; a solid tumour selected from monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma; a tumour of the blood or immune system; or a tumour which originates from acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia; the method comprising administering to a patient a compound of formula I or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, including mixtures thereof in all ratios: in which R R R R A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, Cl and/or Br, and/or in which one or two CH Ar denotes phenyl, naphthyl or biphenyl, each of which is unsub-stituted or mono-, di- or trisubstituted by Hal, A, OR Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OR Het Het Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 1, 2, 3 or 4.